Phospholipid Nanoparticles for Nitric Oxide Modulation in MODS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple organ dysfunction syndrome (MODS) are ineffective in improving organ function, as anti-inflammatory agents have failed to show efficacy, and existing medications like Levophed and nitric oxide synthase inhibitors have adverse effects, leading to increased mortality and organ failure.
Innovation Solution
Administration of a phospholipid nanoparticle (PN) composition comprising a lipophilic or hydrophobic component, amphiphilic emulsifier, polar liquid carrier, and electrolytes, which forms liposomes and micelles with specific diameters, to effectively manage nitric oxide levels and improve blood pressure and organ function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory agents are administered to treat MODS, then inflammation is targeted, but they fail to show efficacy in improving organ function
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach from anti-inflammatory agents to phospholipid nanoparticle compositions that modulate nitric oxide levels. This parameter change addresses the contradiction by shifting from a mechanism that failed (anti-inflammatory) to one that succeeds (nitric oxide modulation via PN composition), improving reliability while maintaining ease of administration.
Solution Approach 2:
The invention uses a composite phospholipid nanoparticle composition containing multiple components (phospholipids, cholesterol, lipophilic drugs) that work synergistically. This composite material approach resolves the contradiction by combining substances that individually may not be effective, creating a formulation that successfully improves organ function in MODS patients.
2Stress or pressure
If Levophed (vasoconstrictor) is administered to treat hypotension, then blood pressure increases, but organ damage worsens
Solution Approach 1:
The patent converts the harmful effect of uncontrolled nitric oxide (which causes vasodilation and hypotension) into a beneficial therapeutic target. By using phospholipid nanoparticles to sequester and modulate nitric oxide levels, the treatment transforms the harmful vasodilatory effect into a controlled mechanism that improves blood pressure without causing organ damage, thus converting harm into benefit.
Solution Approach 2:
The phospholipid nanoparticle composition acts as an intermediary substance between nitric oxide and the vascular system. Rather than directly administering vasoconstrictors that damage organs, the PN composition mediates the interaction by binding and modulating nitric oxide, achieving blood pressure control while protecting organs from direct exposure to harmful vasoconstrictors.
3Quantity of substance
If nitric oxide synthase inhibitor (546C88) is administered to reduce nitric oxide, then nitric oxide levels decrease, but mortality increases and multiple organ failure worsens
Solution Approach 1:
The patent applies local quality by using phospholipid nanoparticles that selectively bind and sequester nitric oxide in specific locations (vascular compartment) rather than systemically inhibiting nitric oxide synthesis. This localized approach reduces nitric oxide where it causes harm (vasodilation) while maintaining adequate levels elsewhere for essential functions, thus improving reliability while controlling nitric oxide quantity.
Solution Approach 2:
The invention employs partial action by partially reducing nitric oxide levels through phospholipid nanoparticle binding, rather than completely inhibiting synthesis. This partial reduction is sufficient to control hypotension and improve organ function without completely eliminating nitric oxide, which would cause excessive adverse effects and increased mortality.
4Stress or pressure
If vasopressor medications are administered to MODS patients, then blood pressure response is sought, but responsiveness is markedly decreased and treatment fails
Solution Approach 1:
The patent applies preliminary action by first administering phospholipid nanoparticle composition to restore nitric oxide balance and vascular responsiveness before or instead of vasopressors. This preliminary modulation of nitric oxide levels prepares the vascular system to respond appropriately to subsequent treatments, improving both blood pressure control and overall treatment responsiveness in MODS patients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PN composition reduces or prevents MODS by effectively redistributing nitric oxide, improving blood pressure, and enhancing organ function, as demonstrated by increased mean arterial blood pressure and improved lung and kidney function in clinical examples.
Implementation Method 1
the PN composition comprises liposomes and/or micelles having a mean diameter of 1-500 nm
Implementation Method 2
the PN composition comprises liposomes and/or micelles having a mean diameter of 1-500 nm
Data Source
AI summary
A PN composition for treating multiple organ dysfunction syndrome (MODS) comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and/or liposomes organized as a lipid bilayer and/or other particle configurations. This is a PN composition that takes up nitric oxide and releases it with enhanced rapidity enabling it to shift the balance of nitric oxide from one that exacerbates organ damage and decreased survivability to one that reverses and/or inhibits organ damage and increases survivability.